Rodman & Renshaw analyst Tony Buter downgraded Atara Biotherapeutics (ATRA) to Neutral from Buy with a price target of $7, down from $25, after the FDA placed a clinical hold on the company’s active investigational new drug applications
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics reports clinical hold placed on Ebvallo programs, ATA3219
- Atara Biotherapeutics price target lowered to $17 from $21 at Canaccord
- Atara Biotherapeutics trading resumes
- Atara Biotherapeutics remains eligible for $60M milestone payment
- Atara announces Ebvallo CRL did not find clinical efficacy deficiencies